Skip to main content
. 2017 Feb 7;8:14232. doi: 10.1038/ncomms14232

Figure 4. FPR agonist Cmpd17b reduces cardiac necrosis 24 h post I–R injury in vivo.

Figure 4

(a) Representative 2,3,5-triphenyltetra-zolium chloride (TTC)-stained LV transverse slices after 24 h reperfusion in mice allocated to vehicle, Cmpd17b or Cmpd43 (both 50 mg kg−1 i.p.)-treatment groups (scale bar, 1 mm). Areas stained dark blue, white and red represented non-risk, infarcted and ischaemic but non-infarcted zones, respectively. Pooled data for (b) AAR (calculated as total infarcted plus ischaemic but non-infarcted zones, % total LV). (c) Myocardial infarct size (%AAR) and (d) plasma cTnI levels. Results are expressed as mean±s.e.m., with n (number of mice) per group indicated below the x axis. #P<0.05, ##P<0.01, ###P<0.001 and ####P<0.0001 versus sham; *P<0.05 and **P<0.01 versus vehicle-treated I–R on one-way ANOVA with Dunnett's post hoc test. Shams (open symbols); I–R (black symbols); Cmpd17b (blue symbols); Cmpd43 (red symbols).